Objective To explore the relationship between nutritional status and sarcopenia in patients with chronic kidney disease. Methods This study included 310 patients with chronic kidney disease (assigned to the kidney disease group) and 150 healthy volunteers who underwent physical examinations during the same period (assigned to the healthy group) between May 2022 and October 2024.The clinical data and related nutritional indicators were compared between the two groups, and the correlation between nutritional status indicators and clinical parameters was analyzed. According to the presence or absence of sarcopenia in the kidney disease group, the patients were divided into a sarcopenia group (n=107) and a non-sarcopenia group (n=203). The nutritional indicators were compared between the two subgroups, the correlation between patients' nutritional status and sarcopenia was analyzed, and the value of nutritional status indicators in diagnosing sarcopenia was evaluated. Results BMI, 25(OH)D3, total body water, muscle mass, and adipose mass in the kidney disease group were significantly lower than those in the healthy group (P<0.05), while the UA, SCr, TC, TG, LDL-C, BUN, CRP, and UACR were significantly higher than those in the healthy group (P<0.05). BMI, 25(OH)D3, total body water, and muscle mass in the kidney disease group were significantly negatively correlated with UA, SCr, CRP, TC, TG, and LDL-C (P<0.05), while UACR was significantly positively correlated with UA, SCr, CRP, TC, TG, and LDL-C (P<0.05). BMI, 25(OH)D3, total body water, and total muscle volume in the sarcopenia group were significantly lower than in the non-sarcopenia group (P<0.05), whereas UACR was significantly higher (P<0.05). BMI, 25(OH)D3, total body water, and muscle mass were protective factors against sarcopenia (OR < 1, P < 0.05), whereas UACR was a risk factor associated with sarcopenia (OR > 1, P < 0.05). The AUCs of BMI, 25 (OH) D3, UACR, total body water, and muscle mass for predicting sarcopenia were 0.614, 0.786, 0.881, 0.675, and 0.734, respectively. The combined diagnostic AUC was 0.951, indicating higher diagnostic value. Conclusion In patients with chronic kidney disease, decreases in BMI, 25(OH)D3, total body water, and muscle mass, and an increase in UACR, can all indicate the occurrence of sarcopenia. Among these, BMI, 25(OH)D3, total body water, and muscle mass serve as nutritional status indicators, and their combination with UACR has auxiliary diagnostic value for sarcopenia.

This paper summarizes clinical experience in treating acne based on the staged therapeutic principles of "eruption in warm diseases". It is considered that acne results from wind-heat retained in the lungs， invading the ying level and obstructing the blood collaterals， and is primarily a disorder involving both the wei and ying systems. In clinical practice， the treatment emphasizes the use of acrid-cool and sweet-cold methods. The core prescription is namely Yinqiaosan Qu Douchi Jia Xishengdi Danpi Daqingye Bei Xuanshen Fang （from Epidemic Warm Diseases ［《温病条辨》］）， and is adjusted according to the stage of disease. In the non-inflammatory stage， when the pathogen initially attacks the wei level， treatment focuses on acrid-cool herbs to release the exterior， with supplementary bitter-sweet ingredients such as Yejuhua （Chrysanthemum Indicum）. In the inflammatory stage， with pronounced heat toxin in the qi level affecting the ying and blood， and local stagnation of qi and blood， the approach is to clear heat and resolve toxin， using blood-cooling and stasis-resolving herbs early to prevent progression. Herbs such as Pugongying （Taraxacum Mongolicum）， Zihuadiding （Viola Yedoensis）， Tiankuizi （Semiaquilegia Adoxoides）， Chonglou （Paris Polyphylla）， Machixian （Portulaca Oleracea）， Zaojiaoci （Gleditsia Sinensis）， Chuanshanjia （Manis Pentadactyla） may be added. In the post-inflammatory erythema stage， when yin of the ying level is depleted and internal deficiency-heat arises， sweet-cold herbs are recommended to nourish the stomach and generate fluids， with the possible addition of Yiwei Decoction （益胃汤）.

ObjectiveTo evaluate the clinical curative effect and security by performing the clinical study ofYinggencao formula in treatment of psoriasis vulgaris with blood-heat TCM syndrome.MethodsA total of 75 patients, diagnosed with Psoriasis Vulgaris Blood-heat RCM syndrome, were randomizedly divided into the treatmeat group with 39 patients and the control group with 36. The treatment group tookYinggencao formula twice daily, while the control group tookQingdai capsules three times daily. All the patients were treated 12 weeks. PASI scores were used as the main outcome and to estimate the curative effect rates.ResultsThe PASI scores of patients in the treatment group (6.97 ± 2.02vs. 16.88 ± 2.91;t=14.380,P=0.009) and the control group (13.14 ± 3.18vs. 17.49 ± 2.32;t=7.780,P=0.013) after treatment showed significantly lower than the scores before. The PASI scores showed significant difference between the two groups after the treatment (P=0.027). The total effective rate of treatment group was significantly higher than the control group (76.9%vs. 61.1%;χ2=5.120, P<0.05).Conclusions TheYinggencao formula therapy showed better effect thanQingdai capsules therapy in treatment of psoriasis vulgaris with blood-heat TCM syndrome.